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Abstract
Mice with constitutive activation of parathyroid hormone (PTH) receptor signaling in osteocytes
(DMP1-caPTHR1 transgenic mice) exhibit increased bone mass and remodeling, two of the
recognized skeletal actions of PTH. Moreover, similar to PTH administration, DMP1-caPTHR1
mice exhibit decreased expression of the osteocyte-derived Wnt antagonist Sost/sclerostin. We
now report that PTH receptor activation also regulates in vivo and in vitro the expression of
fibroblast growth factor 23 (FGF23), an osteocyte product involved in inorganic phosphate (Pi)
homeostasis and bone mineralization. Whole bones and osteocytes, but not osteoblasts, from
DMP1-caPTHR1 mice exhibit elevated FGF23 expression, which is corrected in double transgenic
mice overexpressing Sost in osteocytes. PTH, PTH related protein (PTHrP), or a cAMP stable
analog, increase FGF23 transcripts in a time- and dose-dependent manner in osteocyte-containing
calvarial cell cultures. Circulating FGF23 is also elevated in DMP1-caPTHR1 mice; however,
plasma Pi or renal Pi reabsorption is not altered. Furthermore, the FGF23 receptor complex
comprising FGFR1 and KLOTHO is expressed in osteoblastic cells; and FGFR1, GALNT3, as
well as downstream targets of FGF23 signaling, are increased in osteocytes but not in osteoblasts
from DMP1-caPTHR1 mice. Thus, PTH receptor signaling has the potential to modulate the
endocrine and auto/paracrine functions of osteocytes by regulating FGF23 through cAMP- and
Wnt-dependent mechanisms.
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Introduction
Increasing evidence points to osteocytes, terminally differentiated cells of the osteoblastic
lineage and most abundant bone cells, as regulators of several actions of parathyroid
hormone (PTH) on the skeleton. Thus, PTH inhibits the expression of sclerostin, the product
of the Sost gene that inhibits bone formation by antagonizing the BMP and Wnt pathways
[1, 2]. Furthermore, transgenic mice expressing a constitutively active PTH receptor 1
exclusively in osteocytes (DMP1-caPTHR1 mice) exhibit increased bone mass and elevated
bone remodeling [3, 4], recapitulating two main actions of PTH on bone.
Osteocytes produce fibroblast growth factor-23 (FGF23) [5-8], a hormone produced in bone
that plays a crucial role in phosphate (Pi) homeostasis by inhibiting its renal reabsorption
[9]. FGF23 is protected from degradation into N- and C-terminal fragments by glycosylation
controlled by the galactosaminyl transferase GALNT3. Inactivating mutations of this
enzyme result in reduced intact FGF23 leading to hyperphosphatemia and ectopic
calcification in tumoral calcinosis [10]. Conversely, supraphysiologic FGF23 levels found in
several genetic disorders and in FGF23-producing tumors cause decreased renal Pi
reabsorption and hypophosphatemia resulting in osteomalacia and rickets [10]. Consistent
with the findings in the human diseases, transgenic mice overexpressing FGF23 are
hypophosphatemic [11] whereas FGF23 knockout mice are hyperphosphatemic, condition
that is reversed by FGF23 overexpression in osteoblastic cells [12-14]. Furthermore, FGF23
neutralizing antibodies elevate serum Pi and increase renal expression of the sodium-Pi co-
transporter NPT2A in mice [15].
High dietary Pi and the active form of Vitamin D3, 1,25-dihydroxy-vitamin D3 (1,25-D3) are
major stimulators of FGF23 secretion [16-19]. FGF23 is a marker of altered phosphate
metabolism that increases before detectable changes in PTH in early CKD [20]. However,
several pieces of evidence suggest that PTH might also regulate FGF23 production. Thus,
the hyperphosphatemia exhibited by chronic kidney disease (CKD) patients is accompanied
by elevation in both FGF23 and PTH [10, 21]; and parathyroidectomy prevented the
increase in FGF23 in a rat model of kidney failure [22]. FGF23 is also elevated in patients
and in a mouse model of primary hyperparathyroidism [23, 24]. Moreover, a patient with
Jansen’s metaphyseal chondrodysplasia expressing a constitutively active PTHR1 receptor
mutant exhibit high FGF23 concentrations in the circulation, despite low Pi and normal
1,25-D3 levels [25].
In the current study, we present evidence demonstrating that FGF23 production is
augmented by direct action of the PTH receptor in osteocytes, in vivo in transgenic mice
expressing a Jansen’s constitutively active PTH receptor under the control of an osteocyte-
specific promoter as well as in vitro in primary cultures containing osteocytes treated with
the ligands of the PTHR1. Although circulating Pi or renal Pi reabsorption is not altered,
FGF23 signaling is activated in bones of DMP1-caPTHR1 mice. Thus, regulation of FGF23
in osteocytes represents a potential mechanism by which signaling through the PTH receptor
influences systemic and local FGF23 actions.
Materials and Methods
Animals
DMP1-caPTHR1 and DMP1-Sost transgenic mice were generated by microinjection of
purified DNA into pronuclei of C57BL/6 mice, as previously described [3, 4]. Mouse
colonies were maintained by breeding mice hemizygous for the transgene with wild type
C57BL/6 mice. DMP1-caPTHR1 mice were crossed with DMP1-Sost mice to obtain mice
expressing both the DMP1-caPTHR1 and the DMP1-Sost transgenes [4]. Mice expressing
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green fluorescent protein (GFP) in osteocytes (DMP1-GFP) were provided by Dr. David W.
Rowe and were maintained as homozygous [26]. The α-KLOTHO null mice (KLOTHO −/
−) were from Lexicon Genetics, Inc. (The Woodlands, TX). Animals were fed a regular diet
(Harlan/Teklad #7001, Harlan Laboratories Inc., Frederick, MD), water ad-libitum and
exposed to a 12h light/dark cycle. Whole tibiae, ulnae, calvaria, and kidneys from 6-week-
old mice (males and females) were snapped frozen at sacrifice and stored at −80°C until
used for RNA isolation. Protocols were approved by the Institutional Animal Care and Use
Committee of Indiana University School of Medicine.
Cell culture
Osteoblastic cells were obtained from calvarial bones of neonatal C57BL/6 mice and
cultured at an initial density of 5×104/cm2 for 5-6d in the presence of α-MEM supplemented
with 10% fetal bovine serum and 50μg/ml ascorbic acid. Half of the medium was replaced
by fresh medium every other day. Cultures were treated with vehicle, 50 nM bovine
PTH(1-34) (Bachem, Torrance, CA), 10 nM 1,25-D3 (Enzo Life Sciences International,
Plymouth Meeting, PA), 50 nM human PTHrP (1-34), (Bachem, Torrance, CA), or 1mM
DBA (Enzo Life Sciences International, Inc., Plymouth Meeting, PA) for the times indicated
in the figures, or with different concentrations of PTH(1-34) for 3h. We have previously
shown that these culture conditions promote the formation of osteocytes, as evidenced by
the progressive increase in Sost mRNA expression and detection of sclerostin by
immunohistochemistry [1]. Furthermore, in cultures established with osteoblastic cells from
DMP1-GFP mice, sclerostin expression co-localized with GFP expression in cells exhibiting
dendritic morphology [1].
Quantification of gene expression in isolated osteocytes and osteoblasts
Homozygous DMP1-GFP mice were crossed with hemizygous DMP1-caPTHR1 mice to
generate DMP1-GFP-positive offspring with and without the DMP1-caPTHR1 transgene.
Calvaria cells were isolated from 3-6 day-old mice [3]. In each sorting experiment, cells
from 6-12 mice per genotype (WT or DMP1-caPTHR1 mice) were pooled before sorting
and GFP-expressing cells (osteocytes) were separated from GFP-negative cells (a population
mainly composed of osteoblasts) using a FACSAria flow cytometer (BD Biosciences,
Sparks, MD) at the Flow Cytometry Core Facility of Indiana University School of Medicine.
RNA from GFP-positive and GFP-negative cells was isolated immediately after sorting [3].
Gene expression is expressed as fold change versus the expression of the corresponding
gene in osteocytes from WT mice within each sorting experiment. Results from 3-5
independent sorting experiments are shown.
Quantitative RT-PCR
Total RNA was purified from tissue or cell preparations using Ultraspec reagent (Biotecx
Laboratories, Houston, TX) according to the manufacturer’s instructions. RNA was reverse-
transcribed using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA). Gene expression was analyzed in triplicates by quantitative PCR using the ΔCt method
as previously described [3]. FGF23 and RANKL primer probe sets were purchased from
Applied Biosystems (Mm00445621_m1 and Mm00441908_m1, respectively). KLOTHO
primer probe set was designed in-house and were as follows: probe:
ttgcccacaacctacttttggctcatg, forward primer: cagctccaggctcgggta, reverse primer:
aggtgttgtagagatgccagacttt, as reported earlier [27]. Sequencing confirmed that the cDNA
PCR product was mouse α-KLOTHO mRNA. For the other genes, primer probe sets were
designed using the Assay Design Center of Roche Applied Science (Indianapolis, IN), and
were as follows. For FGFR1: probe 66, forward primer: tctggcctctacgcttgc, reverse primer:
gaggatgggagtgcatctg; GALNT3: probe 20, forward primer: cgctcacgttcttagatgctc, reverse
primer: tatcctggccagcagagg; SOST: probe #16, forward primer: tcctgagaacaaccagacca,
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reverse primer: gcagctgtactcggacacatc; EGR1: probe 22, forward primer
cctatgagcacctgaccaca, reverse primer tcgtttggctgggataactc; EGR2: probe 60, forward primer:
ctacccggtggaagacctc, reverse primer: aatgttgatcatgccatctcc; and ribosomal protein S2 (used
as house-keeping gene): probe 45, forward primer: cagaatggtaggaaggtcacg, reverse primer:
gatcctgctctggaaatcgt.
Biochemistry measurements and Pi tubular reabsorption measurement
Blood was drawn from the facial vein at the indicated times. Calcium, Pi, and creatinine
measurements were performed at the General Clinical Research Center of Indiana
University School of Medicine using a Roche Cobas Mira S Chemistry analyzer (Roche
Diagnostics, Indianapolis, IN). Plasma 1,25-D3 concentrations were determined by ELISA
(Immunodiagnostic Systems Inc., Scottsdale, AZ). Serum intact FGF23 concentration was
measured by ELISA (Kainos Laboratories Inc., Tokyo, Japan) [25]. To determine Pi tubular
reabsorption, 4-5 mice were housed in metabolic cages with free access to water and food,
and urine was collected over a 24 h-period. Urine samples were centrifuged (3000 g, 5 min,
4°C) and stored at −80°C for further analysis. Blood was drawn from the facial vein at the
end of the urine collection time after 3h-fasting and plasma was obtained. Urinary Pi (UP)
and creatinine (UCr) and plasma Pi (PP) and creatinine (PCr) were measured using the
Roche Cobas Mira S Chemistry analyzer. Pi tubular reabsorption was calculated using the
formula 1-[(UP/PP)/(UCr/PCr)] × 100.
Immunohistochemistry
NPT2A was detected in cryosections of kidney using a rabbit anti-mouse NPT2A (gift of
Drs. Heini Murer and Jurg Biber) followed by a chicken anti-rabbit AlexaFluor 594-
conjugated secondary antibody (Invitrogen, Carlsbad, CA), as published [28]. KLOTHO
was detected in paraffin-embedded tibiae sections using a rat monoclonal anti-mouse
KLOTHO antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by a goat anti-rat
horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology). Tibial
bone sections from KLOTHO knockout mice and non-immune IgG were used as negative
controls. KLOTHO −/− bone sections were also stained with goat polyclonal anti-mouse
sclerostin antibody (R&D Systems, Minneapolis, MN) followed by rabbit anti-goat
conjugated with horseradish peroxidase (Santa Cruz Biotechnology), as previously
published [4]. Color was developed with a diaminobenzidine substrate chromogen system
(Dako Corp., Carpinteria, CA). Kidney sections from WT and KLOTHO −/− mice were
stained with the rat anti-KLOTHO antibody followed by AlexaFluor 488-conjugated
chicken anti-rat antibody (Invitrogen, Carlsbad, CA) [28]. Imaging was done with a Leica
DM5000B fluorescence microscope (Leica Microsystems, Inc., Bannockburn, IL) with a
SPOT camera and analysis software (Diagnostic Instruments, Sterling Heights, MI) or with
an Olympus BX51 microscope attached to an OsteoMeasure High Resolution Digital Video
System (OsteoMetrics, Inc., Decatur, GA).
Statistical analysis
Data were analyzed using SigmaStat (SPSS Science) and are expressed as means ± standard
deviations (SD). Differences between means were evaluated using Student’s t-test or two-
way ANOVA.
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Results
FGF23 expression is upregulated by PTH receptor signaling in osteocytes in vivo and in
vitro
Prompted by evidence that PTH acts directly on osteocytes to regulate Sost/sclerostin
expression [1, 2], we examined whether PTH also regulates the expression of FGF23, a
hormone produced by osteocytes that, as PTH, regulates phosphate metabolism [29]. FGF23
mRNA transcripts were elevated in bones from DMP1-caPTHR1 mice with constitutive
activation of the PTH receptor in osteocytes compared to littermates not expressing the
transgene (WT) (Figure 1A). To distinguish whether osteocytes, osteoblasts, or both cell
types were expressing higher FGF23, DMP1-caPTHR1 mice were crossed with DMP1-GFP
transgenic mice in which osteocytes are labeled with GFP; and gene expression was
examined in GFP-positive (osteocytes) and GFP-negative (osteoblasts) cells separated by
fluorescence activated cell sorting of neonatal calvaria cell preparations, as previously
reported [3]. The osteocyte-specific Sost gene was highly expressed in GFP-positive cells
obtained from mice with or without the DMP1-caPTHR1 transgene, whereas it was
practically undetectable in GFP-negative cells, confirming the identity of the cell
populations (Figure 1B). Sost expression was lower in osteocytes derived from mice
expressing the DMP1-caPTHR1 transgene, consistent with our previous findings in this
mouse model [3] and with the reported inhibition of Sost expression by PTH administration
to mice [1, 2]. On the other hand, FGF23 transcripts were detected at similar levels in both
osteocytes and osteoblasts in WT mice. In addition, only osteocytes derived from DMP1-
caPTHR1 mice expressed higher FGF23 levels compared to osteocytes from littermate WT
controls, whereas no difference was found in osteoblasts (Figure 1B), demonstrating that the
source of the elevated FGF23 in the transgenic mice is the osteocytes. FGF23 expression
was not high in bones of double transgenic mice expressing DMP1-caPTHR1 and the human
Sost gene under the control of the same DMP1 promoter (Figure 1C), suggesting that FGF23
regulation by PTH receptor signaling in osteocytes requires Wnt signaling.
The addition of 50 nM PTH for 0.5-24 h to osteocyte-containing primary cultures of calvaria
cells from WT mice lead to marked increases in FGF23 mRNA (Figure 1D). Maximal
effects were observed at 3 h; and in 7 independent experiments the increases varied between
3 to 200-fold compared to vehicle-treated cultures. PTH increased FGF23 mRNA
expression in a dose-dependent manner, with significant increases observed with as low as
0.5 nM PTH and maximal effects found with 50 nM (Figure 1E). PTH enhanced FGF23
expression to a similar extent in the presence or absence of 1,25-D3 (10−8 M) (Figure 1F).
Treatment with 1,25-D3 alone did not affect FGF23 expression. However, 1,25-D3 did
stimulate the expression of RANKL, a recognized target gene of this hormone, confirming
the functionality of 1,25-D3 in these culture conditions. PTH also increased RANKL
expression, consistent with published evidence [30], and addition of both hormones
simultaneously increased RANKL expression to a greater extent than either hormone alone.
These data confirm that PTH increases FGF23 expression independently of 1,25-D3. Similar
to PTH, PTHrP (50 nM), the other ligand of the PTH receptor 1, or to the stable analog of
cAMP DBA (1 mM), at 3, 8, and 24 h of treatment, upregulated FGF23 mRNA expression
(Figure 1G). In contrast, and consistent with our previous findings with PTH [1], Sost
expression was decreased by these stimuli.
PTH receptor activation in osteocytes increases circulating levels of FGF23 but does not
affect plasma Pi levels or Pi reabsorption in the kidney
Increased FGF23 production in bones and in osteocytes was accompanied by higher levels
of the hormone in the circulation of DMP1-caPTHR1 mice compared with WT littermates
(Figure 2A). Circulating 1,25-D3 was also elevated in the transgenic mice (Figure 2B).
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Plasma Pi and calcium levels were within normal range (Figure 2C); and Pi reabsorption in
the kidney (Figure 2D) or NPT2A protein expression in the renal proximal tubule (Figure
2E) or NPT2A mRNA (not shown) were similar in the transgenic mice compared to WT
littermates. We next examined whether the lack of detectable changes in Pi handling in the
transgenic mice was due to decreased expression of components of the high affinity FGF23
receptor complex [31], as recently reported for parathyroid cells of CKD rats [32]. However,
expression of FGFR1 or KLOTHO were not different in kidneys of DMP1-caPTHR1 mice
compared to WT littermates (Figure 2F), excluding a potential resistance to FGF23 in the
kidneys of the transgenic mice.
We next examined the possibility that the increase in FGF23 expression in osteocytes would
activate signaling locally in bones of DMP1-caPTHR1 mice. FGFR1 is expressed in most
cells; whereas KLOTHO, the co-receptor essential for intracellular signaling, is expressed in
a limited number of organs including kidney, the primary site of FGF23 action [29, 33].
Binding of FGF23 to FGFR1/KLOTHO triggers phosphorylation of FGFR substrate 2 and
the extracellular signal regulated kinases (ERKs), followed by increased expression of early
growth response genes (EGR) 1 and 2. We found that both FGFR1 and KLOTHO transcripts
are expressed in bone and in osteocytes and osteoblasts of both WT and DMP1-caPTHR1
mice (Figures 3A and B). The level of expression of KLOTHO mRNA in bone lysates as
well as in isolated osteocytes and osteoblasts, is approximately 500 times lower than in
kidney (Ct for calvaria 31 versus Ct for kidney 22). Nevertheless, the KLOTHO protein is
readily detected in osteocytes as well as osteoblast by immunostaining of bone sections
(Figure 3C). No changes in KLOTHO were found in the transgenic mice. Specificity of the
detection of the protein is confirmed by lack of staining in bone and kidney sections from
KLOTHO −/− mice. On the other hand, FGFR1 expression is increased in bones and
specifically in osteocytes of DMP1-caPTHR1 mice (Figures 3A and B). Expression of
GALNT3, the enzyme that protects FGF23 from degradation, is also elevated in osteocytes
of DMP1-caPTHR1 mice (Figure 3D). As for the expression of FGF23, increased GALNT3
expression was not observed in DMP1-caPTHR1 mice also expressing Sost in osteocytes.
Consistent with elevated FGF23 and the presence of the FGF23 receptor complex, the
downstream targets of FGF23 signaling EGR1 and EGR2 are also high in bones of DMP1-
caPTHR1 mice (Figure 3E).
Discussion
The findings of this study demonstrate that activation of PTH receptor signaling in vivo in
mice expressing a constitutively active PTHR1 in osteocytes or in vitro by ligands of this
receptor, increases FGF23. A simultaneous increase in GALNT3 stabilizes FGF23, leading
to elevation of intact FGF23 in the circulation and locally in bone, where FGF23 binds to the
FGFR1/KLOTHO complex expressed in both osteocytes and osteoblasts and activates
intracellular signaling (Figure 4).
The elevated FGF23 in the circulation of DMP1-caPTHR1 mice is consistent with a recent
report demonstrating marked and persistent high plasma FGF23 in a patient of Jansen’s
metaphyseal chondrodysplasia expressing ubiquitously the same constitutively active
PTHR1 mutant as our transgenic mice [25]. This patient exhibits hypophosphatemia,
suggesting that FGF23 was increased by factor(s) other than high Pi levels. Our findings
demonstrating that FGF23 is increased by activation of the PTHR1 in osteocytes through
cAMP- and Wnt-dependent signaling provide a mechanistic explanation for the
phenomenon.
Because FGF23 can act in the kidney and locally in bone, our current findings suggest that,
through FGF23, PTH has the potential to modulate not only the endocrine but also the auto/
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paracrine function of osteocytes. Although the antibodies available to detect KLOTHO
cannot distinguish between membrane-bound and soluble forms of the protein, we found
that the FGF23/MAPK target genes EGR1/2 are elevated in bones of the DMP1-caPTHR1
mice. This is consistent with earlier reports demonstrating actions of FGF23 in bone [34,
35]. Analysis of the skeletal phenotype of the DMP1-caPTHR1 mice previously reported
shows no apparent overall mineralization defect [3, 4]. However, there is an increase in
osteoid perimeter/bone perimeter and in osteoid width in cancellous bone, suggestive of
delayed mineralization [4]. This effect might result from increased FGF23 signaling locally
in bone cells, independent of changes in circulating Pi, as suggested by previous reports [5,
6]. In contrast, the systemic consequences of FGF23 regulation are not apparent in our
transgenic mice. Thus, Pi levels in plasma are normal and Pi tubular reabsorption and
NPT2A expression in the kidney are not decreased in DMP1-caPTHR1 mice, as it would be
expected in a FGF23 provoked state. The reason(s) for the inability of increased FGF23 to
affect Pi handling in the kidney in our transgenic mice is not known. We have excluded the
possibility that the expression of components of the FGF23 receptor complex is decreased in
the kidney of DMP1-caPTHR1 mice, which could explain the resistance to FGF23 elevation
(similar to what it was recently reported for parathyroid cells in a rat model of CKD [32]). A
potential explanation for the lack of changes in circulating Pi is that the increase in FGF23
observed in DMP1-caPTHR1 mice is not sufficient to elicit a change in Pi reabsorption in
the kidney. Indeed, the elevation in FGF23 levels in DMP1-caPTHR1 mice is relatively
lower compared to other models in which changes in Pi reabsorption are detected.
Moreover, FGF23 is expressed by both osteocytes and osteoblasts, and although PTH or
PTHrP markedly increase FGF23 in vitro in the mixed osteoblast/osteocyte cultures, FGF23
expression is elevated modestly and only in osteocytes in vivo in our model of PTH receptor
activation driven by the DMP1 promoter. Therefore, it is possible that the in vivo effect of
PTHR1 activation on Pi homeostasis would require the contribution of osteoblast-derived
FGF23.
FGF23 has been shown to suppress 1,25-D3 production in the kidney [36]. However, this
previously established inhibitory effect of FGF23 on 1,25-D3 production is not observed, as
circulating levels of 1,25-D3 are not decreased and 1-α-hydroxylase expression in the kidney
was not reduced (not shown) in DMP1-caPTHR1 mice. On the contrary, plasma 1,25-D3 is
elevated in the transgenic mice suggesting that other mechanisms are responsible for the
increase. One stimulator of 1,25-D3 production is PTH. However, PTH levels are normal in
the DMP1-caPTHR1 mice. In addition, we have demonstrated that the 8kb fragment of the
DMP1 promoter used to drive the expression of the constitutively active PTH receptor is not
expressed in kidney [3, 4], thereby excluding the possibility of unwanted activation of
PTHR1 signaling that could have increased 1,25-D3 production in the kidney. A potential
scenario that reconciles our findings is one in which increased FGF23 in the DMP1-
caPTHR1 mice would have initially caused a drop in Pi levels in the circulation with the
resulting increase in 1,25-D3 production. Elevated 1,25-D3 could have then increased
intestinal Pi absorption and renal Pi reabsorption [37] leading to normalization of circulating
Pi levels. This situation could also explain the apparent lack of response of the kidney to
increased FGF23 since a FGF23-induced decrease in NPT2A expression and Pi reabsorption
would be opposed by a 1,25-D3-induced increase in these parameters.
1,25-D3 is one of the major stimulators of FGF23 secretion [16-19]. However, it is unlikely
that increased circulating 1,25-D3 is the cause of elevated FGF23 production in DMP1-
caPTHR1 mice since, if that were the case, both osteoblasts and osteocytes should be
affected and only osteocytes express more FGF23 in DMP1-caPTHR1 mice. Moreover,
PTH, PTHrP or the cAMP analog increase FGF23 expression in vitro, in the absence of
1,25-D3, confirming that FGF23 is directly regulated by PTH receptor signaling.
Furthermore, the effect of PTH on FGF23 expression in cultured calvaria cells was not
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affected by addition of 1,25-D3. Although we did not observed an effect of short-term
treatment with 1,25-D3 in our experiments, it has been previously shown that 1,25-D3
increases FGF23 expression in rat calvaria cells and the rat osteosarcoma cell lines
ROS17/2.8 and UMR106 [38-40]. Thus, future investigations are warranted to determine
whether PTH and 1,25-D3 have additive or synergistic effects on FGF23 regulation at longer
periods of culture.
Our findings showing that the increase in FGF23 expression by PTH receptor signaling is
abolished in mice overexpressing Sost in osteocytes suggests that PTH regulates FGF23
through a mechanism that requires elevation of Wnt signaling. This is consistent with
previous studies demonstrating that stabilization of β-catenin induced by LiCl increases
FGF23 promoter reporter activity in osteoblastic cells [41] and that sclerostin blunts PTH-
stimulated FGF23 expression in osteosarcoma cells [22]. The fact that FGF23 expression is
increased in osteocytes and not in osteoblasts of the DMP1-caPTHR1 mice suggests that the
increase in FGF23 results from a cell autonomous effect of Wnt signaling in the osteocyte
and that does not involve paracrine effects of Wnt activation on osteoblasts. Further studies
are required to clarify the mechanism of this phenomenon.
It has been long recognized that systemic elevation of PTH induces the synthesis of 1,25-D3
in the kidney; and that, in turn, 1,25-D3 inhibits PTH secretion by the parathyroid glands.
More recent studies revealed that 1,25-D3 stimulates FGF23 production in bone [39]; and
that, conversely, FGF23 suppresses 1,25-D3 production as well as PTH secretion [42]. Our
findings that PTH stimulates FGF23 expression add a novel feedback loop to the interactive
hormonal mechanisms that control mineral homeostasis. Moreover, this evidence points to
osteocytes as potential therapeutic targets in the management of conditions exhibiting
dysregulation of PTH and FGF23, such as CKD.
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Abbreviations
PTH parathyroid hormone
DMP1-caPTHR1 dentin matrix protein 1-constitutively active PTH receptor 1 mice
FGF23 fibroblast growth factor 23
PTHrP PTH related protein
FGFR1 FGF receptor 1
GALNT3 galactosaminyl transferase 3
BMP bone morphogenetic protein
Pi inorganic phosphate
NPT2A sodium-phosphate co-transporter
1,25-D3 1,25-dihydroxy-vitamin D3
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CKD chronic kidney disease
GFP green fluorescent protein
DBA dibutyrylcyclic AMP
MEM minimal essential medium
SD standard deviation
ANOVA analysis of variance
WT wild type
ERKs extracellular signal regulated kinases
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Research highlights
• Parathyroid hormone (PTH) exerts its anabolic and pro-remodeling actions, at
least in part, through receptors expressed in osteocytes.
• PTH decreases expression of the osteocyte-derived Wnt antagonist Sost/
sclerostin, a potent inhibitor of bone formation.
• We now show that PTH receptor activation in osteocytes increases FGF23, an
osteocyte product that inhibits kidney phosphate re-absorption.
• FGFR1/KLOTHO receptor complex is expressed in bone cells and FGF23
signaling is increased in bone by PTH receptor activation.
• Thus, PTH receptor signaling has the potential to modulate the endocrine and
auto/paracrine functions of osteocytes through FGF23.
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Figure 1. FGF23 expression is upregulated by PTH receptor signaling in osteocytes in vivo and in
vitro
A. FGF23 mRNA expression in bones of 6-week-old DMP1-caPTHR1 mice. Bars indicate
means ± SD of 4-6 mice per group; *p < 0.05 vs. WT littermates by Student’s t-test.
B. FGF23 and Sost mRNA expression in osteocytes (OT) and osteoblasts (OB) isolated by
GFP sorting of neonatal calvaria cell preparations from DMP1-GFP mice expressing or not
the DMP1-caPTHR1 transgene. Each symbol represents an independent sorting experiment
in which 6-12 mice of each genotype were pooled before sorting. Results from 4 or 5
experiments for FGF23 or Sost expression, respectively, expressed as fold change versus
WT OT for each preparation, are shown. *p < 0.05 vs. WT OT, by Student’s t-test.
C. FGF23 mRNA expression in ulnar bones of DMP1-caPTHR1, DMP1-Sost, double
transgenic, and WT littermates. Bars indicate means ± SD of 4-6 mice each group; *p < 0.05
vs. WT littermates, by Student’s t-test.
D and E. Time- and dose-response to PTH on FGF23 expression in cultures containing
osteocytes and osteoblasts. Bars indicate means ± SD of triplicate determinations; *p < 0.05
versus the respective vehicle treated group, by Student’s t-test.
F. Effect of PTH (50 nM), 1,25-D3 (10 nM) or both for 3 h on FGF23 and RANKL
expression in cultures containing osteocytes and osteoblasts. Bars indicate means ± SD of
triplicate determinations; *p < 0.05 versus vehicle treated group and #p < 0.05 versus PTH-
treated group, by 1-way ANOVA.
G. Effect of PTH (50 nM), PTHrP (50 nM), and DBA (1mM) on FGF23 expression in
cultures containing osteocytes and osteoblasts. Bars indicate means ± SD of triplicate
determinations; *p < 0.05 versus vehicle treated group by 1-way ANOVA.
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Figure 2. PTH receptor activation in osteocytes increases circulating levels of intact FGF23 but
has no detectable effects on Pi tubular reabsorption or Pi or calcium plasma concentrations
A, B, C. FGF23, 1,25-D3, Pi, and calcium (Ca) concentrations in plasma from DMP1-
caPTHR1 mice and WT littermates of the indicated ages. Bars are means ± SD; n=3-5/
group; *p < 0.05 versus WT littermates of the same age, by Student’s t-test.
D. Renal tubular reabsorption of Pi of DMP1-caPTHR mice and WT littermates. Bars are
means ± SD; n=4-5/group.
E. NPT2A protein expression measured by immunofluorescence in kidney sections of
DMP1-caPTHR1 mice and WT littermates.
F. FGFR1 and KLOTHO expression in kidney from DMP1-caPTHR1 mice and WT
littermates. Bars indicate means ± SD; n=4/group.
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Figure 3. PTH receptor activation in osteocytes enhances FGF23 signaling in bone
A. FGFR1 and KLOTHO mRNA expression in bones from DMP1-caPTHR1 mice and WT
littermates. Bars indicate means ± SD; n=5-6 for ulnae, and n=3-4 for calvaria. *p < 0.05 vs.
WT littermates, by Student’s t-test.
B. FGFR1 and KLOTHO mRNA expression in osteocytes (OT) and osteoblasts (OB) of
DMP1-caPTHR1 mice (black symbols) or WT littermates (white symbols). Each symbol
indicates an independent sorting experiment. *p < 0.05 vs. WT littermates by Student’s t-
test.
C. KLOTHO protein expression was detected in bone by immunohistochemistry using anti-
KLOTHO antibody; non-immune IgG was used as negative control. Tibial bone sections
from WT, DMP1-caPTHR1, and KLOTHO deficient (KLOTHO −/−) mice were used. Anti-
sclerostin antibody was used to demonstrate that the KLOTHO −/− bone sections are intact.
Kidney sections from WT and KLOTHO −/− mice were used to demonstrate the specificity
of the anti-KLOTHO antibody. Bars indicate 10 μm.
D. GALNT3 mRNA expression in bones or OT and OB from DMP1-caPTHR1 mice and
WT littermates, or in ulnar bones of DMP1-caPTHR1, DMP1-Sost, double transgenic, and
WT littermates. Bars indicate means ± SD of 3-8 mice; *p < 0.05 versus WT littermates,
WT OT, or double transgenic mice, by Student’s t-test.
E. EGR1 and EGR2 mRNA expression in bones from DMP1-caPTHR1 mice or littermate
controls. Bars indicate means ± SD of 3-6 mice per group; *p < 0.05 vs. WT littermates, by
Student’s t-test.
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Figure 4. PTH receptor signaling modulates the endocrine and auto/paracrine function of
osteocytes by upregulating FGF23 expression
In vivo activation of cAMP by a constitutively active PTHR1 or in vitro by the PTHR1
ligands, PTH and PTHrP, or DBA, increases FGF23 and inhibits Sost expression. A
simultaneous increase in GALNT3 stabilizes FGF23, leading to increased intact FGF23 in
the circulation as well as locally in bone. Binding of FGF23 to the FGFR1/KLOTHO
receptor complex expressed in osteocytes and osteoblasts activates intracellular signaling.
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